 Julie Harral
Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 16 | 2023 | 1894 | 0.740 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 6 | 2011 | 51 | 0.400 |
Why?
| | Anemia, Sickle Cell | 3 | 2020 | 253 | 0.370 |
Why?
| | Lung | 13 | 2023 | 3937 | 0.360 |
Why?
| | Pulmonary Artery | 10 | 2022 | 1097 | 0.320 |
Why?
| | Heart Ventricles | 7 | 2023 | 781 | 0.320 |
Why?
| | Hypoxia | 7 | 2023 | 1085 | 0.280 |
Why?
| | Hemoglobins | 2 | 2019 | 339 | 0.260 |
Why?
| | Microvessels | 3 | 2018 | 82 | 0.250 |
Why?
| | Exercise Tolerance | 2 | 2025 | 273 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2012 | 444 | 0.230 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2025 | 30 | 0.230 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2025 | 56 | 0.230 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 236 | 0.200 |
Why?
| | Animals | 28 | 2025 | 35404 | 0.190 |
Why?
| | Endothelial Cells | 5 | 2023 | 749 | 0.190 |
Why?
| | Scleroderma, Systemic | 1 | 2022 | 114 | 0.180 |
Why?
| | Mice | 20 | 2025 | 16982 | 0.180 |
Why?
| | Vascular Remodeling | 2 | 2022 | 192 | 0.180 |
Why?
| | Cigarette Smoking | 1 | 2022 | 91 | 0.180 |
Why?
| | Beta vulgaris | 1 | 2020 | 11 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 231 | 0.170 |
Why?
| | Disease Models, Animal | 8 | 2025 | 4076 | 0.170 |
Why?
| | Emulsions | 1 | 2019 | 51 | 0.160 |
Why?
| | Pulmonary Emphysema | 1 | 2022 | 275 | 0.160 |
Why?
| | Pulmonary Edema | 1 | 2019 | 106 | 0.160 |
Why?
| | Mice, Transgenic | 8 | 2025 | 2135 | 0.160 |
Why?
| | Respiratory Tract Infections | 1 | 2023 | 376 | 0.160 |
Why?
| | Evans Blue | 1 | 2018 | 7 | 0.150 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 68 | 0.150 |
Why?
| | Blood Vessels | 3 | 2016 | 187 | 0.150 |
Why?
| | Capillary Permeability | 1 | 2018 | 141 | 0.140 |
Why?
| | Fluorocarbons | 1 | 2019 | 109 | 0.140 |
Why?
| | Physical Exertion | 1 | 2018 | 210 | 0.140 |
Why?
| | Rats | 8 | 2022 | 5485 | 0.130 |
Why?
| | Down Syndrome | 1 | 2023 | 478 | 0.130 |
Why?
| | Fibrosis | 1 | 2019 | 526 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 337 | 0.130 |
Why?
| | Water | 1 | 2019 | 442 | 0.130 |
Why?
| | Neprilysin | 1 | 2016 | 48 | 0.130 |
Why?
| | Ventricular Remodeling | 2 | 2023 | 255 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 6 | 2019 | 2403 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2007 | 259 | 0.120 |
Why?
| | Muscle Contraction | 1 | 2018 | 423 | 0.120 |
Why?
| | Endotoxins | 1 | 2015 | 220 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 521 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1000 | 0.110 |
Why?
| | Cell Proliferation | 5 | 2018 | 2378 | 0.110 |
Why?
| | Altitude | 1 | 2018 | 462 | 0.110 |
Why?
| | Calcium Channels, T-Type | 2 | 2005 | 94 | 0.110 |
Why?
| | Macrophages | 2 | 2019 | 1489 | 0.100 |
Why?
| | Oxygen | 1 | 2018 | 916 | 0.100 |
Why?
| | Apoptosis | 4 | 2018 | 2489 | 0.100 |
Why?
| | Muscle, Skeletal | 2 | 2025 | 1644 | 0.100 |
Why?
| | Vitamin D | 1 | 2015 | 380 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 902 | 0.100 |
Why?
| | Cytoskeleton | 1 | 2011 | 184 | 0.090 |
Why?
| | Hemolysis | 2 | 2025 | 199 | 0.090 |
Why?
| | Histone Deacetylases | 1 | 2012 | 212 | 0.080 |
Why?
| | Transgenes | 2 | 2008 | 178 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 209 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2147 | 0.080 |
Why?
| | Ventricular Function, Right | 3 | 2023 | 276 | 0.080 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2023 | 145 | 0.080 |
Why?
| | Gene Expression Regulation | 4 | 2016 | 2545 | 0.080 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 74 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2022 | 5468 | 0.070 |
Why?
| | Mutant Proteins | 1 | 2008 | 100 | 0.070 |
Why?
| | Blood Pressure | 5 | 2018 | 1736 | 0.070 |
Why?
| | Mice, Inbred Strains | 1 | 2008 | 408 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 2008 | 160 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 142 | 0.070 |
Why?
| | Proteomics | 2 | 2025 | 1058 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 756 | 0.070 |
Why?
| | Galectin 1 | 1 | 2006 | 2 | 0.070 |
Why?
| | Pulmonary Circulation | 3 | 2019 | 431 | 0.070 |
Why?
| | Hyperoxia | 1 | 2007 | 90 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2012 | 4102 | 0.060 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2006 | 85 | 0.060 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 35 | 0.060 |
Why?
| | Multigene Family | 1 | 2006 | 195 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2006 | 176 | 0.060 |
Why?
| | Male | 11 | 2023 | 63691 | 0.060 |
Why?
| | Leukocyte Common Antigens | 3 | 2008 | 82 | 0.050 |
Why?
| | Femur | 1 | 2006 | 243 | 0.050 |
Why?
| | Pneumonia | 1 | 2009 | 619 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 462 | 0.050 |
Why?
| | Stem Cells | 1 | 2007 | 578 | 0.050 |
Why?
| | Erythrocytes | 2 | 2025 | 673 | 0.050 |
Why?
| | Biology | 1 | 2023 | 85 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 84 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2271 | 0.050 |
Why?
| | Female | 10 | 2023 | 68751 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 477 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 111 | 0.050 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2001 | 20 | 0.050 |
Why?
| | Doxycycline | 2 | 2016 | 59 | 0.050 |
Why?
| | Humans | 14 | 2025 | 129687 | 0.040 |
Why?
| | Leukocytes | 1 | 2022 | 306 | 0.040 |
Why?
| | Familial Primary Pulmonary Hypertension | 2 | 2011 | 199 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 274 | 0.040 |
Why?
| | Cell Division | 3 | 2009 | 790 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2015 | 371 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 978 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 3705 | 0.040 |
Why?
| | Nitrates | 1 | 2020 | 88 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 953 | 0.040 |
Why?
| | Phenylpropionates | 1 | 2019 | 18 | 0.040 |
Why?
| | Animals, Newborn | 2 | 2015 | 834 | 0.040 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2019 | 28 | 0.040 |
Why?
| | Pyridazines | 1 | 2019 | 54 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1204 | 0.040 |
Why?
| | Metabolomics | 1 | 2025 | 652 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2001 | 311 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 427 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 171 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 78 | 0.040 |
Why?
| | AC133 Antigen | 2 | 2008 | 19 | 0.040 |
Why?
| | Kidney Tubules, Proximal | 1 | 2019 | 125 | 0.040 |
Why?
| | Tamoxifen | 1 | 2019 | 197 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 62 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 1264 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2019 | 121 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2001 | 583 | 0.040 |
Why?
| | Signal Transduction | 2 | 2011 | 4935 | 0.040 |
Why?
| | Cell Lineage | 1 | 2019 | 332 | 0.040 |
Why?
| | Pyrroles | 1 | 2018 | 202 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2020 | 672 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 166 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2011 | 812 | 0.030 |
Why?
| | Microcirculation | 2 | 2007 | 145 | 0.030 |
Why?
| | Glycoproteins | 2 | 2008 | 338 | 0.030 |
Why?
| | Substance P | 1 | 2016 | 43 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2020 | 532 | 0.030 |
Why?
| | Duodenum | 1 | 2016 | 76 | 0.030 |
Why?
| | Antigens, CD | 2 | 2008 | 487 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 485 | 0.030 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2015 | 30 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 1875 | 0.030 |
Why?
| | Phosphorylation | 2 | 2011 | 1716 | 0.030 |
Why?
| | Indoles | 1 | 2018 | 386 | 0.030 |
Why?
| | Elastin | 1 | 2015 | 77 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2007 | 1090 | 0.030 |
Why?
| | Phenotype | 3 | 2011 | 3062 | 0.030 |
Why?
| | Blotting, Western | 2 | 2009 | 1204 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2007 | 590 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2011 | 1213 | 0.030 |
Why?
| | Transfection | 2 | 2007 | 918 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 1686 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2018 | 896 | 0.030 |
Why?
| | Peptides | 2 | 2008 | 926 | 0.030 |
Why?
| | Genotype | 2 | 2011 | 1829 | 0.030 |
Why?
| | rac GTP-Binding Proteins | 1 | 2011 | 32 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2011 | 53 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2628 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 12 | 0.020 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2011 | 54 | 0.020 |
Why?
| | Neuropeptides | 1 | 2011 | 72 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2011 | 45 | 0.020 |
Why?
| | Chronic Disease | 2 | 2008 | 1723 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 203 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2009 | 2888 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 284 | 0.020 |
Why?
| | Gene Expression | 2 | 2009 | 1465 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 129 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 463 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1160 | 0.020 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2009 | 50 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 51 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 23 | 0.020 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2009 | 66 | 0.020 |
Why?
| | Smad Proteins | 1 | 2008 | 40 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2011 | 1310 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 458 | 0.020 |
Why?
| | Hematocrit | 1 | 2008 | 93 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 478 | 0.020 |
Why?
| | Systole | 1 | 2008 | 191 | 0.020 |
Why?
| | Endothelium | 1 | 2008 | 121 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2009 | 199 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2006 | 3184 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 184 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 349 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 277 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 84 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 568 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 296 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2007 | 128 | 0.020 |
Why?
| | Rats, Nude | 1 | 2006 | 27 | 0.020 |
Why?
| | Cell Cycle | 1 | 2008 | 583 | 0.020 |
Why?
| | DNA Primers | 1 | 2006 | 508 | 0.020 |
Why?
| | Time Factors | 2 | 2007 | 6545 | 0.020 |
Why?
| | Mibefradil | 1 | 2005 | 7 | 0.020 |
Why?
| | Muscle Proteins | 1 | 2007 | 222 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 10221 | 0.010 |
Why?
| | Capillaries | 1 | 2006 | 103 | 0.010 |
Why?
| | Diltiazem | 1 | 2005 | 28 | 0.010 |
Why?
| | Electrocardiography | 1 | 2008 | 611 | 0.010 |
Why?
| | Edema | 1 | 2006 | 124 | 0.010 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2004 | 18 | 0.010 |
Why?
| | Cycloheximide | 1 | 2004 | 55 | 0.010 |
Why?
| | Caspase 8 | 1 | 2004 | 48 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 42 | 0.010 |
Why?
| | Patch-Clamp Techniques | 1 | 2005 | 277 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 44 | 0.010 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2004 | 41 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2004 | 94 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2004 | 182 | 0.010 |
Why?
| | Sheep | 1 | 2006 | 845 | 0.010 |
Why?
| | Caspases | 1 | 2004 | 245 | 0.010 |
Why?
| | Actins | 1 | 2006 | 410 | 0.010 |
Why?
| | Organ Specificity | 1 | 2004 | 295 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 716 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 6412 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2142 | 0.010 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2004 | 319 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2006 | 508 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 378 | 0.010 |
Why?
| | Telomerase | 1 | 2004 | 231 | 0.010 |
Why?
| | Tritium | 1 | 2001 | 75 | 0.010 |
Why?
| | Cyclin E | 1 | 2001 | 23 | 0.010 |
Why?
| | Thymidine | 1 | 2001 | 60 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 74 | 0.010 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2001 | 39 | 0.010 |
Why?
| | Mutagenesis | 1 | 2001 | 179 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2008 | 2702 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 126 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2748 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2014 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1937 | 0.010 |
Why?
| | Blood Proteins | 1 | 2001 | 245 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2007 | 1900 | 0.010 |
Why?
| | Mitochondria | 1 | 2004 | 875 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1441 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 5759 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 3969 | 0.010 |
Why?
| | DNA | 1 | 2001 | 1406 | 0.010 |
Why?
| | Hypertension | 1 | 2001 | 1242 | 0.010 |
Why?
| | Child | 1 | 2008 | 20882 | 0.000 |
Why?
| | Middle Aged | 1 | 2008 | 31165 | 0.000 |
Why?
| | Adult | 1 | 2008 | 35607 | 0.000 |
Why?
|
|
Harral's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|